Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16959483 | 0.94 | CYP4F2 (0.52) | CYP4F2CYP4A11ACHEIDO1CHRNB4 | |
| SCHEMBL16555721 | 0.84 | ACHE (0.67) | CYP4F2CYP4A11ACHEIDO1CHRNB4 | |
| SCHEMBL26707682 | 0.84 | CYP4F2 (0.46) | CYP4F2CYP4A11ACHEIDO1CHRNB4 | |
| SCHEMBL11983544 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11ACHEIDO1CHRNB4 | |
| SCHEMBL16961327 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11ACHEIDO1CHRNB4 | |
| SCHEMBL6026873 | 0.82 | CYP4F2 (0.44) | CYP4F2CYP4A11ACHEIDO1CHRNB4 | |
| SCHEMBL16681079 | 0.82 | CYP4F2 (0.44) | CYP4F2CYP4A11ACHEIDO1CHRNB4 | |
| SCHEMBL671597 | 0.82 | CYP4F2 (0.44) | CYP4F2CYP4A11ACHEIDO1CHRNB4 | |
| SCHEMBL17064613 | 0.82 | CYP4F2 (0.44) | CYP4F2CYP4A11ACHEIDO1CHRNB4 | |
| SCHEMBL28917348 | 0.82 | CYP4F2 (0.44) | CYP4F2CYP4A11ACHEIDO1CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 849 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118599572-B | Modified hyperbranched demulsifier and preparation process and application thereof | 东营市金美化工有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-118894783-A | Peripheral halogen functionalized AB3Poly benzyl ether dendrimer gel factor and preparation method and application thereof | 常州大学 | 2024-11-05 | — | — | CN | claimed |
| CN-118599572-A | Modified hyperbranched demulsifier and preparation process and application thereof | 东营市金美化工有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-111303179-A | Synthesis of norcantharidin carboxylic acid difluoro benzyl ester and anti-tumor application thereof | 遵义医科大学 | 2020-06-19 | — | — | CN | claimed |
| CN-111233883-A | Norcantharidin fluorine-containing benzyl ester salt derivative, synthesis method and anti-tumor application | 遵义医科大学 | 2020-06-05 | — | — | CN | claimed |
| CN-107597018-B | A kind of double-hydrophilic parents oil-based surfactant and preparation method thereof | 陕西莱特光电材料股份有限公司 | 2019-06-11 | — | — | CN | claimed |
| CN-109810572-A | Inorganic nano material prints ink and its preparation method and application | 深圳TCL工业研究院有限公司 | 2019-05-28 | — | — | CN | claimed |
| CN-109789135-A | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-05-21 | — | — | CN | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-7691556-B2 | Antireflective compositions for photoresists | AZ ELECTRONIC MATERIALS USA CORP. (US) | 2010-04-06 | — | — | US | claimed |
| WO-2001077097-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001077079-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001068605-A1 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| EP-1115695-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CYP4F2 1537/4885CYP4A11 1735/4885ACHE 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.